Observational studyEBioMedicine2020
Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
Observational study in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.Journal of neurology · 2023Pooled it
- Pooled it
- Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2022Trial
- Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.European journal of neurology · 2021Trial
- Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2021Trial
- Article
- GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.Brain : a journal of neurology · 2026Article
- Neurofilaments: A Promising Diagnostic and Prognostic Biomarker in Multiple Sclerosis.Annals of neurosciences · 2026Review
- Choroid plexus enlargement associates with serum neurofilament and predicts relapse-free progression in multiple sclerosis.Cell reports. Medicine · 2026Article
- Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Differential Biomarkers of Response to Dimethyl Fumarate and Ocrelizumab in Multiple Sclerosis.International journal of molecular sciences · 2026Article
- Effects of disease-modifying drugs on serum neurofilament light chain, chitinase-3-like-1 protein levels, and selected plasmacytoid dendritic cell biomarkers in relapsing-remitting multiple sclerosis.African journal of laboratory medicine · 2026Article
- Evaluating the potential of sNfL as a biomarker in MS management in the UK: insights from SUNLIT survey.BMC neurology · 2025Article
- Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens.Journal of neurology · 2025Article
- Neurofilament Light Chains in Serum Predict Post-Transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy.MedComm · 2025Article
- Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non-Optic Neuritis Onset.European journal of neurology · 2025Article
- Gene expression signatures from whole blood predict amyotrophic lateral sclerosis case status and survival.Nature communications · 2025Article
- Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice.International journal of molecular sciences · 2025Review
- Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis.EBioMedicine · 2025Review
- Glial Fibrillary Acid Protein Reflects Disease Activity in Autoimmune Encephalitis.European journal of neurology · 2025Article
- Increased Disability Progression in rs10191329Annals of neurology · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
32 authors at 19 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients.
methodsIn a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up.
findingsOf 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with existing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213; p = 0.036). sNfL levels correlated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-naïve patients (11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.4-15.3 pg/ml, n = 88). Therapy escalation decisions within this period were reflected by longitudinal changes in sNfL levels.
interpretationAssessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis and may, particularly when measured longitudinally, facilitate therapeutic decisions.
fundingSupported the German Federal Ministry for Education and Research, the German Research Council, and Hertie-Stiftung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.